Kilitch Drugs (India) Ltd. | Small-cap | Healthcare
₹350.80
-0.47%
| Kilitch Drugs Stock Comparison:
Kilitch Drugs vs Sun PharmaceuticalKilitch Drugs vs Divi's LaboratoriesKilitch Drugs vs Innova CaptabKilitch Drugs vs Sequent ScientificKilitch Drugs vs Sun Pharma AdvancedKilitch Drugs vs NIFTY 50 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 431.4M
Gross Profit 176.8M 40.98%
Operating Income 24.2M 5.61%
Net Income 22.6M 5.24%
EPS (Diluted) ₹1.84

Balance Sheet Metrics

Total Assets 3.1B
Total Liabilities 1.1B
Shareholders Equity 2.0B
Debt to Equity 0.56

Cash Flow Metrics

Revenue & Profitability Trend

Kilitch Drugs Income Statement From 2021 to 2025

Metric20252024202320222021
Revenue i2.0B1.5B1.4B1.1B681.3M
Cost of Goods Sold i1.1B804.7M771.3M682.5M381.2M
Gross Profit i904.9M731.4M617.2M447.1M300.1M
Gross Margin % i45.9%47.6%44.5%39.6%44.0%
Operating Expenses
Research & Development i-----
Selling, General & Administrative i49.6M48.7M26.5M26.8M28.3M
Other Operating Expenses i388.8M301.2M274.1M213.8M140.3M
Total Operating Expenses i438.4M349.9M300.6M240.6M168.6M
Operating Income i286.3M211.1M143.5M97.6M37.5M
Operating Margin % i14.5%13.7%10.3%8.6%5.5%
Non-Operating Items
Interest Income i35.9M4.1M3.0M2.2M1.7M
Interest Expense i50.4M59.3M49.2M12.0M7.5M
Other Non-Operating Income-----
Pre-tax Income i344.7M193.5M120.1M96.1M51.2M
Income Tax i95.3M57.8M37.3M34.0M13.5M
Effective Tax Rate % i27.7%29.9%31.1%35.4%26.4%
Net Income i249.4M135.8M82.8M62.1M37.7M
Net Margin % i12.6%8.8%6.0%5.5%5.5%
Key Metrics
EBITDA i386.7M272.6M196.7M123.8M70.0M
EPS (Basic) i₹16.24₹9.17₹6.71₹4.73₹2.37
EPS (Diluted) i₹16.24₹9.17₹6.71₹4.73₹2.37
Basic Shares Outstanding i1643386115929314155821291556611015479893
Diluted Shares Outstanding i1643386115929314155821291556611015479893

Income Statement Trend

Kilitch Drugs Balance Sheet From 2021 to 2025

Metric20252024202320222021
Assets
Current Assets
Cash & Equivalents i97.5M189.1M197.9M100.1M124.5M
Short-term Investments i495.6M501.1M393.3M472.3M364.0M
Accounts Receivable i847.4M632.2M542.9M414.1M229.2M
Inventory i215.8M55.8M24.1M52.9M35.9M
Other Current Assets144.7M1.0K108.7M-1.0K49.4M
Total Current Assets i1.7B1.5B1.3B1.1B803.6M
Non-Current Assets
Property, Plant & Equipment i41.1M37.0M35.3M34.1M33.8M
Goodwill i374.2M392.0M407.1M423.6M439.7M
Intangible Assets i3.5M4.4M2.6M2.3M1.5M
Long-term Investments-----
Other Non-Current Assets-2.0K-2.0K2.0K-197.0K-20.0K
Total Non-Current Assets i1.4B940.7M931.2M957.4M1.2B
Total Assets i3.1B2.4B2.2B2.1B2.0B
Liabilities
Current Liabilities
Accounts Payable i541.6M255.9M408.7M428.7M536.5M
Short-term Debt i216.5M316.5M221.9M204.3M148.0M
Current Portion of Long-term Debt-----
Other Current Liabilities2.6M2.1M834.0K955.0K5.7M
Total Current Liabilities i843.1M642.2M688.7M692.8M733.2M
Non-Current Liabilities
Long-term Debt i277.7M----
Deferred Tax Liabilities i-----
Other Non-Current Liabilities-----
Total Non-Current Liabilities i280.2M1.7M683.0K2.8M3.8M
Total Liabilities i1.1B643.9M689.4M695.5M737.0M
Equity
Common Stock i160.8M160.8M155.8M155.8M154.9M
Retained Earnings i1.1B842.3M696.3M591.8M518.2M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i2.0B1.8B1.5B1.4B1.3B
Key Metrics
Total Debt i494.2M316.5M221.9M204.3M148.0M
Working Capital i896.1M817.8M575.3M448.3M70.5M

Balance Sheet Composition

Kilitch Drugs Cash Flow Statement From 2021 to 2025

Metric20252024202320222021
Operating Activities
Net Income i344.7M193.5M120.1M96.1M51.2M
Depreciation & Amortization i-----
Stock-Based Compensation i---0-1.6M
Working Capital Changes i-376.7M-119.6M-133.5M-279.8M-77.1M
Operating Cash Flow i8.2M129.2M32.8M-173.9M-21.7M
Investing Activities
Capital Expenditures i--64.5M-38.1M-82.0M-363.0M
Acquisitions i-----
Investment Purchases i-75.0K-29.6M--69.3M-16.6M
Investment Sales i52.7M-94.3M01.6M
Investing Cash Flow i58.9M-99.5M56.2M-155.0M-390.2M
Financing Activities
Share Repurchases i-----
Dividends Paid i----12.0M-
Debt Issuance i177.8M94.5M17.6M81.3M21.9M
Debt Repayment i-----7.5M
Financing Cash Flow i182.8M241.9M59.6M151.6M38.1M
Free Cash Flow i-293.3M-66.0M-12.3M-24.2M93.6M
Net Change in Cash i250.0M271.6M148.6M-177.3M-373.8M

Cash Flow Trend

Kilitch Drugs Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 20.99
Forward P/E 23.68
Price to Book 2.88
Price to Sales 3.08
PEG Ratio 0.17

Profitability Ratios

Profit Margin 13.65%
Operating Margin 5.61%
Return on Equity 13.32%
Return on Assets 8.54%

Financial Health

Current Ratio 2.06
Debt to Equity 24.66
Beta -0.19

Per Share Data

EPS (TTM) ₹17.26
Book Value per Share ₹125.88
Revenue per Share ₹129.43

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
kilitch6.4B20.992.8813.32%13.65%24.66
Sun Pharmaceutical 3.9T37.285.3715.08%19.29%3.26
Divi's Laboratories 1.6T69.9310.8014.64%23.89%0.03
Innova Captab 49.4B37.875.1213.37%9.98%35.24
Sequent Scientific 46.9B157.766.442.84%1.85%62.47
Sun Pharma Advanced 46.7B-13.68-21.57157.88%-53.22%-1.24

Financial data is updated regularly. All figures are in the company's reporting currency.